Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,280 questions in 114 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 37.5%Ungraded 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Colchicine (oral) vs placebo Duration of attackse,f · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | 1 study · 9 participants | Very low |
Anakinra vs placebo Duration of attacks · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Anakinra vs placebo Time between attacks · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Anakinra vs placebo Prevention of AA amyloidosis · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Anakinra vs placebo Adverse drug reactions · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | RR 0.54 [0.12, 2.44] | 1 study · 25 participants | Moderate |
Anakinra vs placebo Acute‐phase response · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | 1 study · 20 participants | Moderate |
Canakinumab vs placebo Number of participants experiencing an attacka · people with colchicine‐resistant familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | RR 0.41 [0.26, 0.65] | 1 study · 63 participants | Moderate |
Canakinumab vs placebo Duration of attacks · people with colchicine‐resistant familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Canakinumab vs placebo Time between attacks · people with colchicine‐resistant familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Canakinumab vs placebo Prevention of AA amyloidosis · people with colchicine‐resistant familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Canakinumab vs placebo Adverse drug reactions · people with colchicine‐resistant familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | 1 study · 63 participants | Moderate |
Colchicine (oral) vs placebo Time between attackse,f · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | 1 study · 11 participants | Very low |
Canakinumab vs placebo Acute‐phase response · people with colchicine‐resistant familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | 1 study · 63 participants | Moderate |
Colchicine single dose vs divided dose Number of participants experiencing an attack · children with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine single dose vs divided dose Duration of attacksa · children with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | 1 study · 79 participants | Moderate |
Colchicine single dose vs divided dose Time between attacks · children with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine single dose vs divided dose Prevention of AA amyloidosis · children with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine single dose vs divided dose Adverse drug reactions · children with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | 1 study · 79 participants | Moderate |
Colchicine single dose vs divided dose Acute‐phase response · children with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | 1 study · 39 participants | Low |
Colchicine (oral) vs placebo Prevention of AA amyloidosis · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine (oral) vs placebo Adverse drug reactions · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | 1 study · 11 participants | Very low |
Colchicine (oral) vs placebo Acute‐phase response · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Rilonacept vs placebo Number of participants experiencing an attacka · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | RR 0.87 [0.59, 1.26] | 1 study · 14 participants | Moderate |
Rilonacept vs placebo Duration of attacksa · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | 1 study · 14 participants | Low |
Rilonacept vs placebo Time between attacksa · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | 1 study · 14 participants | Low |
Inhaled nitric oxide vs placebo Time to pain resolution · adults and children with SCD Inhaled nitric oxide for treating pain crises in people with sickle cell disease (2022) · Cochrane | no estimate extracted | 1 study · 150 participants | Low |
Inhaled nitric oxide vs placebo Frequency of pain crises in the · adults and children with SCD Inhaled nitric oxide for treating pain crises in people with sickle cell disease (2022) · Cochrane | RR 0.73 [0.31, 1.71] | 1 study · 150 participants | Low |
Inhaled nitric oxide vs placebo Frequency of pain crises in the · adults and children with SCD Inhaled nitric oxide for treating pain crises in people with sickle cell disease (2022) · Cochrane | RR 0.53 [0.25, 1.11] | 1 study · 150 participants | Low |
Inhaled nitric oxide vs placebo Adverse events · adults and children with SCD Inhaled nitric oxide for treating pain crises in people with sickle cell disease (2022) · Cochrane | no estimate extracted | 1 study · 150 participants | Low |
Exercise vs ACBT Pulmonary function: absolute change FEV1 % predicted · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | 1 study · 18 participants | Very low |
Exercise plus PD&P vs PD&P only Quality of Life: change in CFQ‐R score · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise plus PD&P vs PD&P only Adverse effects · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | 1 study · 17 participants | Very low |
Exercise plus PD&P vs PD&P only Participant preference · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise plus PD&P vs PD&P only Adherence · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | 1 study · 17 participants | Very low |
Exercise plus PD&P vs PD&P only Need for extra antibiotics (days) · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Pulmonary function: absolute change FEV1 % predicted · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Change in VO2 peak during maximal exercise · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Quality of life: change in CFQ‐R score · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Adverse effects · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | 1 study · 13 participants | Very low |
Exercise vs underwater PEP (uPEP; also known Participant preference: VAS test and a questionnaire to evaluate acceptability of technique to participants · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | 1 study · 13 participants | Very low |
Exercise vs ACBT Change in VO2 peak during maximal exercise · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Adherence · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Need for extra antibiotics (days) · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs ACBT Quality of life · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs ACBT Adverse effects · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | 1 study · 18 participants | Very low |
Exercise vs ACBT Participant preference: VAS score for treatment effectiveness and preference. · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | 1 study · 18 participants | Very low |
Exercise vs ACBT Adherence · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs ACBT Need for extra antibiotics (days) · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise plus PD&P vs PD&P only Pulmonary function: absolute change FEV1 % predicted · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | 2 studies · 55 participants | Very low |
Exercise plus PD&P vs PD&P only Change in VO2 peak during maximal exercise · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |